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Abstract
Background: Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune
genes associated with late onset Alzheimer’s disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma
2 (PLCG2) P522R has been reported to be protective against LOAD.
PLC enzymes are key elements in signal transmission networks and are potentially druggable targets. PLCG2 is highly
expressed in the hematopoietic system. Hypermorphic mutations in PLCG2 in humans have been reported to cause
autoinflammation and immune disorders, suggesting a key role for this enzyme in the regulation of immune cell
function.
Methods: We assessed PLCG2 distribution in human and mouse brain tissue via immunohistochemistry and in situ
hybridization. We transfected heterologous cell systems (COS7 and HEK293T cells) to determine the effect of the P522R
AD-associated variant on enzymatic function using various orthogonal assays, including a radioactive assay, IP-One
ELISA, and calcium assays.
Results: PLCG2 expression is restricted primarily to microglia and granule cells of the dentate gyrus. Plcg2 mRNA is
maintained in plaque-associated microglia in the cerebral tissue of an AD mouse model. Functional analysis of the p.
P522R variant demonstrated a small hypermorphic effect of the mutation on enzyme function.
Conclusions: The PLCG2 P522R variant is protective against AD. We show that PLCG2 is expressed in brain microglia,
and the p.P522R polymorphism weakly increases enzyme function. These data suggest that activation of PLCγ2 and
not inhibition could be therapeutically beneficial in AD. PLCγ2 is therefore a potential target for modulating microglia
function in AD, and a small molecule drug that weakly activates PLCγ2 may be one potential therapeutic approach.
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Background
Alzheimer’s disease is the most common neurodegenera-
tive disorder and the leading cause of dementia. Late on-
set AD is genetically complex, and known susceptibility
loci only explain a proportion of disease heritability [1].
Large-scale genetic studies have led to the identification
of several new susceptibility genes associated with
LOAD. These genetic data, together with an analysis of
biological pathways, implicate processes related to
immune response in the etiology of LOAD and point to
the immune system as a prime target for therapeutic
approaches [2–4]. Amongst the newly discovered poly-
morphisms, rare variants in microglial-related genes
including triggering receptor expression on myeloid
cell-2 (TREM2), ABI family member 3 (ABI3), and
phospholipase C-gamma-2 (PLCG2) have been described
[5, 6]. Notably, the PLCG2 missense variant Pro522Arg
(P = 5.38 × 10−10, OR = 0.68) was associated with decreased
risk of LOAD [6].
PLCG2 belongs to the family of phospholipase C-gamma
and encodes an enzyme (PLCγ2) that cleaves the membrane
phospholipid PIP2 (1-phosphatidyl-1D-myo-inositol
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4,5-bisphosphate) to secondary messengers IP3 (myo--
inositol 1,4,5-trisphosphate) and DAG (diacyl-glycerol)
which further propagate a wide range of downstream
signals. PLCγ2 shares high structural and mechanistic
overlap with the other member of the PLCγ family,
PLCγ1 [7]. Although both enzymes are important for
regulation of specific responses of specialized cells of
the immune system, they show different cell-type ex-
pression and are relevant in very different medical
conditions [7]. PLCG1 is ubiquitously distributed, and
mutations are associated with some forms of cancers,
such as cutaneous T cell lymphoma [8, 9], but also
neuropsychiatric disorders [10]. PLCγ2 is predomin-
antly expressed in the bone marrow and lymphoid or-
gans (Human Protein Atlas available from
www.proteinatlas.org [11]), and PLCG2 variants cause
inherited immune disorders designated as PLAID
(PLCG2-associated antibody deficiency and immune
dysregulation [12] and APLAID (autoinflammatory
PLAID [13]).
In peripheral immune cells, PLCγ2 has been impli-
cated in signaling pathways downstream of the B cell re-
ceptor, and it is thought to modulate the functions of
macrophages, platelets, mast cells, neutrophils, and NK
cells through the Fc receptor [14].
PLCγ2 belongs to the same interaction network as
TREM2 [6] and may be directly involved in its signaling
pathway [15, 16]. TREM2 is a transmembrane receptor
expressed on the membrane of myeloid cells and an im-
portant susceptibility gene for AD [5]. In osteoclasts, ac-
tivation downstream Trem2 initiates a cascade of events,
including phosphorylation and activation of PLCγ2,
amongst other proteins [17]. In microglia, these path-
ways promote several cellular responses including sur-
vival, proliferation, phagocytosis, enhanced secretion of
cytokines, and chemokines [18] and are potentially in-
volved in neurodegenerative processes.
Genomic studies can accelerate the pathways to novel
therapeutics by suggesting promising translational targets
and informing the type of approach to be undertaken. The
identification of naturally occurring genetic variants with
protective effects against diseases represents a valuable
potential resource for drug development [19, 20].
The P522R polymorphism lies within the regulatory
domain of PLCγ2, but its effect on enzyme function is
unknown. Given that the variant is protective against
LOAD, understanding its effect is fundamental in deter-
mining whether a small molecule inhibitor or activator/
stabilizer would be beneficial as a therapeutic.
PLCγ2 spatial expression in resident brain immune
cells and in AD is unexplored. Therefore, we first
characterized its distribution in the brain. We found that
Plcg2 mRNA mainly co-localizes with microglia markers
in healthy brain tissue, as well as in microglia near
amyloid plaques in an amyloid precursor protein (APP)
mouse model of AD. Additionally, functional
characterization of the AD protective variant PLCγ2
p.P522R revealed a small increase in activity compared
to wild type (WT) enzyme. PLCγ2 is therefore a poten-
tial target for modulating microglia function in AD, and




WT mice were maintained on a C57BL6 background at
the Wolfson Institute for Biomedical Research in accord-
ance with UK legislation (ASPA 1986).
TgCRND8 mice were maintained in-house by breeding
APP transgenic males (carrying WT RD gene [21] with
C57B6/C3H F1 females (Envigo). These mice have florid
AD-type Aβ plaque pathology in their forebrains, start-
ing around 3months of age. Animal procedures were ap-
proved by the University of Florida Institutional Animal
Care and Use Committee. All animals were house
grouped, under standard laboratory conditions (12:12-h
light/dark cycle, lights on at 0600 h) with a room
temperature of 21 °C, and water and food available ad
libitum.
Mouse tissue processing, immunohistochemistry (IHC),
and in situ hybridization (ISH)
IHC was carried out as previously described [22]. Pri-
mary antibodies used were the following: rabbit
anti-PLCγ2 (1:50, H160, Santa Cruz Biotechnologies
sc-9015), rabbit anti-PLCγ2 (custom produced and
purified by Pacific Immunology Corp, Ramona, CA,
using the peptide sequence “INSLYDVSRMYV”), rabbit
anti-Iba-1 (ionized calcium binding adaptor molecule 1,
1:500, Q08578, Alpha Laboratories), and rabbit anti-NeuN
(Neuronal Nuclei, 1:500, ABN78, Millipore). Secondary
antibodies (Alexa, Invitrogen) were used at a final dilution
of 1:1000.
Adult mice were perfusion-fixed with 4% paraformal-
dehyde (PFA), and the brains were dissected out and
post-fixed overnight in 4% PFA. Samples were cryopro-
tected by overnight immersion in 20% sucrose, embed-
ded in optimal cutting temperature compound (Tissue
Tek, Raymond Lamb Ltd., Medical Supplies, Eastbourne,
UK) and frozen on dry ice. Fifteen μm-thick cryosections
were collected onto Superfrost slides and ISH (RNA-
Scope Multiplex Fluorescent v2 323110, ACD
Bio-Techne) was carried out according to manufacturer’s
instructions with the following catalog probes:
Mm-Plcg2 474781; Mm-Plcg1-C2 483531-C2;
Mm-Olig2-C2 447091-C2; Mm-Pecam1-C3 316721-C3;
Mm-Slc1a3-C2 430781-C2; Mm-Trem2-C2 404111-C2
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(ACD, Bio-Techne). For some experiments, ISH was
followed by IHC with anti-Iba1.
All sections were counterstained with Hoechst 33258
dye (Sigma, 1000-fold dilution), and the slides were
mounted with Dako Fluorescence Mounting Medium
(DAKO).
Confocal images (z stack height on average 10 μm,
1 μm spacing) were taken on a Zeiss LSM 880 confocal
microscope (Carl Zeiss AG) and processed for contrast
and brightness enhancement with Photoshop (CS5,
Adobe). A final composite was generated in Adobe Illus-
trator (CS5, Adobe).
RNASCope reaction was quantified using CellProfiler
Software [23] on confocal images (2/3 fields per animal
per staining) taken with 40× objective. Dots per cell (nu-
cleus) were counted, and the numbers of cells
co-expressing mRNA (> 1 dot per cell) for Plcg2 and
other markers were calculated. Due to the use of nuclear
staining to identify cell boundaries, this method does
not allow to assess for transcripts quantification in
processes.
Human tissue processing, IHC, and ISH
Post-mortem human frontal cortex formalin-fixed,
paraffin-embedded, 5-μm-thick sections were supplied
by Queen Square Brain Bank for Neurological Disorders,
UCL-Institute of Neurology (London, UK). The tissue is
stored for research under a license from the Human Tis-
sue Authority. Sections were deparaffinized in xylene
and rehydrated in graded ethanol dilutions (100%, 90%,
and 70%). Endogenous non-specific peroxidase activity
was quenched by 0.03% H2O2 (Sigma-Aldrich) in metha-
nol (1:100 dilution) for 5 min, followed by a 10-min anti-
gen retrieval treatment in a pressure cooker. After
blocking with 10% non-fat milk solution for 1 h at RT,
slides were incubated with the primary antibody (rabbit
anti-PLCγ2 H160, Santa Cruz Biotechnologies sc-9015)
overnight at 4 °C (1:50). Sections were incubated with bi-
otinylated anti-rabbit IgG (1:200, Sigma-Aldrich) for 30
min at RT. After three 5-min washes in PBS, sections
were incubated with avidin-biotin complex horseradish
peroxidase (ABC) reagent (Thermo Fisher Scientific) for
30 min. The reaction was developed with diaminobenzi-
dine (DAB) activated by H2O2. Sections were counter-
stained with Mayer’s hematoxylin (RAL Diagnostics).
Sections were dehydrated though increasing concentra-
tions of ethanol (70%, 90%, and 100%) and cleared in
xylene series. Finally, slides were mounted with DPX
(Sigma-Aldrich) and cover slipped.
ISH on human tissue was carried out on frozen
sections. After thawing, slides were fixed with 4% PFA
for 25 min at RT, prior to hybridization with the follow-
ing catalog probes: Hs-PLCG2 506781, HS-PPIB positive
control 313901, and DapB negative control 310043. The
protocol was carried out with a Multiplex Fluorescent v2
kit (323110, ACD Bio-Techne) following manufacturer
instruction, with an added final incubation step for 30 s
with Trueblack Lipofuscin Autofluorescence Quencher
(Insight Biotechnology Ltd) to quench endogenous
fluorescence.
Cell culture and transfections
Plasmids for the expression of full-length human
pEGFPC1-PLCG2 constructs in mammalian cells have
been described previously [24]. PLCG2 is from Origene
([25]). EGFR (epidermal growth factor receptor) con-
struct is a gift from Axel Ullrich (Addgene plasmid #
65225). QuikChange PCR mutagenesis (Stratagene) was
used to introduce the P522R point mutation in the
PLCG2 common variant. All mutants were fully se-
quenced to verify the fidelity of the PCR reaction.
COS7 cells were maintained at 37 °C in a humidified
atmosphere of 95% air and 5% CO2 in Dulbecco’s modi-
fied Eagle’s medium (DMEM, Invitrogen) supplemented
with 10% (v/v) fetal bovine serum (Invitrogen) and 2.5
mM glutamine. Prior to transfection, cells were seeded
into 6-well plates at a density of 2.5 × 105 cells/well and
grown for 16 h in 2 ml/well of the same medium. For
transfection, 1 μg of PLCG2 plasmid DNA was mixed
with 1 μl of PlusReagent™ and 7 μl of Lipofectamine™
(Invitrogen) and added to the cells in 0.8 ml of DMEM
without serum. The cells were incubated for 3.5 h at 37 °C,
5% CO2 before the transfection mixture was removed and
replaced with DMEM-containing serum.
Analysis of inositol phosphate formation in intact COS7
cells
Inositol phosphate formation was assessed as described
in [26]. This is an established, standardized assay that
has been, amongst other applications, successfully used
to assess previously identified disease-linked variants of
PLCG2 [12, 13, 26].
Briefly, 24 h after transfection, the cells were washed
twice with inositol-free DMEM without serum and incu-
bated for 24 h in 1.5 ml of the same medium supple-
mented with 0.25% fatty acid free bovine serum albumin
(Sigma) and 1.5 μCi/ml myo-2-3[H] inositol (MP Bio-
medicals). After a further 24 h, the cells were incubated
in 1.2 ml of inositol-free DMEM without serum contain-
ing 20mM LiCl with or without stimulation with 100
ng/ml EGF (Epidermal Growth Factor, Calbiochem). The
cells were lysed by addition of 1.2 ml of 4.5% perchloric
acid. After incubating the samples on ice for 30 min,
they were centrifuged for 20 min at 3700 × g. Superna-
tants and pellets were separated. The supernatants were
neutralized by addition of 3 ml of 0.5M potassium hy-
droxide/9 mM sodium tetraborate and centrifuged for a
further 20 min at 3700 × g. Supernatants were loaded
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onto AG1-X8 200–400 columns (Bio-Rad) that had been
converted to the formate form by addition of 2M am-
monium formate/0.1 M formic acid and equilibrated
with water. The columns were washed three times with
5 ml of 60 mM ammonium formate/5 mM sodium tetra-
borate, and inositol phosphates were eluted with 5 ml of
1.2M ammonium formate/0.1M formic acid. Five milli-
grams of Ultima-Flo scintillation fluid (PerkinElmer Life
Sciences) was added to the eluates and the radioactivity
quantified by liquid scintillation counting. The values
represent total inositol phosphates. The pellets from the
first centrifugation were resuspended in 100 μl of water,
and 375 μl of chloroform/methanol/HCl (200:100:15)
was added. The samples were vortexed, and an add-
itional 125 μl of chloroform and 125 μl of 0.1M HCl
were added.
After further vortexing, the samples were centrifuged
at 700 × g for 10 min. Ten microliters of the lower phase
were placed in a scintillation vial with 3 ml of
Ultima-Flo scintillation fluid and the radioactivity quan-
tified by liquid scintillation counting. The obtained
values correspond to radioactivity in inositol lipids. PLC
activity is expressed as the total inositol phosphates
formed relative to the amount of [3H]myo-inositol in the
phospholipid pool. Because the differences in
steady-state labeling of inositol lipids are small (within
20%), this normalized PLC activity corresponds closely
to PLC values expressed as total inositol phosphates.
Western blotting
PVDF membranes were blocked in TBS 0.5% casein 1 h
at RT. Antibodies (anti-GFP, 11814460001, Roche; rabbit
anti-PLCγ2 custom produced, rabbit anti-EGFR D38B1,
4267, Cell Signaling Technologies) were diluted in TBS
with 0.2% Tween-20 (TBS-T) and incubated 1 h at RT.
The membranes were washed with TBS-T and Western
blots analyzed with Odyssey infrared imaging system
(LI-COR Inc., NE, USA).
ELISA D-myo-inositol 1-phosphate
D-myo-inositol 1-phosphate (IP1) was quantified by
ELISA IP-One (CISBIO US, Inc., USA) according to the
manufacturer’s instructions. Briefly, HEK293T co-transfected
with EGFR and PLCG2 were stimulated with human
recombinant EGF (Thermo Fisher, Carlsbad, USA)
150 ng/ml for 1 h. Cell lysates were loaded in ELISA
plate for IP1 quantification.
Calcium flux assay
This assay has been successfully used to assess the func-
tion of transiently transfected PLCG1 and 2 [13, 27].
Intracellular calcium (Ca2+) changes were measured
with FURA-2-AM (Invitrogen, USA) based on [28].
Transiently transfected HEK293T cells attached to
poly-L-lysine-treated plate were washed with HBSS
(HBSS-Hepes buffer; 120 mM NaCl, 5.3 mM KCl, 0.8
mM MgSO4, 1.8 mM CaCl2, 10 mM glucose, 20 mM
Hepes, pH 7.4) and loaded with Fura 2-AM (Sigma) for
20 min at RT in the dark. Cells were washed with HBSS
and incubated with HBSS for 30 min at RT. The intra-
cellular Ca2+ changes were measured by alternating the
fluorescence excitation wavelengths 340 and 380 nm and
emitted fluorescence at 510 nm. Data acquisition was
typically at 5-s intervals, and data were presented as
emitted fluorescence ratio 340/380.
Statistical analysis
Statistical analysis was performed using Prism 6 version
6.05 for Windows (GraphPad Software, La Jolla, CA,
USA). Data were analyzed using an appropriate statis-
tical test followed by post hoc one-way ANOVA with
Tukey’s multiple comparison test and two-way ANOVA
with Bonferroni multiple comparisons. Details of the
statistical test used are included in the figure legends.
Results
PLCG2 is expressed in microglia cells throughout the
brain
Recent transcriptomic datasets suggest prominent Plcg2
expression in microglia of the mouse cortex [29–31];
however, spatial mapping of the protein and mRNA in
brain tissue has not been described. To better under-
stand the involvement of this protein in AD, we assessed
PLCγ2 distribution in human cortical tissue. We de-
tected PLCγ2 immunoreactivity in putative microglia of
both white and gray matter, in the human frontal cortex
(Fig. 1a). Due to technical difficulties with the antibodies
used in this study (in one case, the antibody is no longer
commercially available; in other cases, antibodies gave
unspecific or no signal upon IHC on fixed human
post-mortem brain or mouse tissue), we turned to in situ
hybridization (ISH, RNAScope, [32]). RNAScope on hu-
man cortex with a probe specific for PLCG2 confirmed
the sparse distribution pattern observed with immunola-
beling (Additional file 1a). We further investigated the
expression of Plcg2 across the mammalian brain. Since
PLCγ1 seems to be expressed ubiquitously in mamma-
lian tissues, while PLCγ2 is thought to be restricted to
the hematopoietic and immune system [7], we sought to
determine the distribution of these two PLCs in the
brain. We found that Plcg1 and Plcg2 mRNAs show
complementary expression patterns, with very little de-
gree of overlap in the adult mouse brain (Fig. 1b). Label-
ing for Plcg1 was detected in several brain cells,
including large nuclei of putative neurons of the cortex
(Fig. 1b). Conversely, Plcg2 reaction product was found
in sparse cells, in cortical as well as subcortical regions,
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including the olfactory bulb, neocortex, hippocampus
CA1, and substantia nigra (Additional file 1b).
In line with the single-cell RNA-seq profiling data-
bases of the mouse cortex (see above), we confirmed a
high degree of co-localization between Plcg2 mRNA and
the microglia-specific marker IBA-1 in cortical gray and
white matter of the adult mouse brain. In these regions,
all IBA1-immunoreactive microglia cell bodies contained
transcripts for Plcg2 (100%, Fig. 1c). We further vali-
dated high degree of co-expression between the two
markers in subcortical brain regions, including the thal-
amus and the cerebellum (data not shown).
To determine whether other brain cell types express
Plcg2, we quantified co-localization between Plcg2 and
other glial/endothelial cell markers. We found only occa-
sional co-expression with markers for astrocytes (Glast
GLutamate ASpartate Transporter/Slc1a3 Solute Carrier
family 1 member 3, 5.8 ± 3.8%, Additional file 2a), endo-
thelial cells (Pecam1, platelet and endothelial cell adhe-
sion molecule 1, 9.6 ± 1.44%, Additional file 2b), and
oligodendrocyte-lineage cells (Olig2, oligodendrocyte
transcription factor 2, 1.6 ± 2.2% Additional file 2c).
In addition to a generally scattered labeling in most
brain areas, we found intense Plcg2 RNAScope reaction
product in the granule cell layer of the hippocampal
dentate gyrus, where the Plcg2 signal co-localizes with
the neuronal marker NeuN (Additional file 2d). Rare
co-labeling with NeuN was also detected in other sub-
cortical regions (not shown). In summary, Plcg2 tran-
scripts are primarily restricted to microglia cells across
the mouse brain, with the exception of the pronounced
expression seen in granule cells in the dentate gyrus.
PLCG2 in microglia in Alzheimer’s disease
PLCG2 mRNA upregulation has been reported in cortical
tissue of LOAD patients (FC, 1.35; p = 0.0028, [33]) and in
transgenic mice carrying mutations associated with early
AD (APP KM670/671 NL, PNSEN1 M146V) or over-
expressing the human tau-4R/2N isoform (P301L) [34, 35].
However, normalization to microglia-specific genes (e.g.,
Abi3) and data from single-cell profiling of brain immune
cells [6, 36, 37], suggest that apparent PLCG2 transcript
upregulation in bulk tissue is mostly related to microgliosis
occurring as a consequence of neurodegeneration.
Recent findings point to microglia heterogeneity in
neurodegeneration [36, 38]. To determine whether het-
erogeneity in Plcg2 expression might be observed in




Fig. 1 PLCγ2 expression in the human and mouse cortical microglia. a IHC for PLCγ2 on the gray and white matter of the human prefrontal cortex. b
Multiplex RNAScope for Plcg2 and Plcg1 on the adult mouse cortex. Small and big arrows point to RNASCope reaction for Plcg2 and Plcg1, respectively.
c RNAScope for Plcg2 followed by IHC for IBA-1 on the gray and white matter of the adult mouse cortex. Arrows point to co-expression of the two
markers. Ctx cortex, CC corpus callosum, Hp hippocampus
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brain of a transgenic mouse model overexpressing the
human APP with the Swedish (KM670/671NL) and Indi-
ana (V717F) mutations (TgAPPswe/ind [21]). Plcg2 ap-
peared to be equally expressed in microglia surrounding
the plaques in the cortical regions of 6 months old trans-
genic mice (Fig. 2a) as compared to localization in
microglia in control non-transgenic littermates (Fig. 2b).
Next, we assessed whether in the brain Plcg2
co-localizes with the GWAS AD risk gene Trem2, as
suggested by protein-protein interaction network models
[6]. Indeed, we detected co-expression of Plcg2 and
Trem2 mRNAs in the cell soma and processes of puta-
tive cortical and hippocampal microglia (Fig. 3).
AD associated PLCG2 p.P522R variant shows a weak
hypermorphic activity
Germline deletion and point mutations in PLCG2 cause
complex immune disorders and autoinflammatory dis-
ease in humans [12, 13]. Similarly, two hypermorphic
Plcg2 mutations in mice (Ali5, Abnormal limb 5,
D993G; Ali14, Abnormal limb 14, Y495C) lead to severe
autoinflammation and antibody deficiencies [26, 39, 40].
Stimulation of the PLC enzymes increases the hydrolysis
of PIP2, producing IP3 (further converted to other inosi-
tol phosphates) and DAG. Binding of IP3 on its receptor
induces intracellular Ca2+ release from the Ca2+ stored
in endoplasmic reticulum. The effects of the above
mutations on enzyme function have been determined by
quantifying the production of inositol phosphates or the
release of intracellular Ca2+ following stimulation with
epidermal growth factor (EGF) in heterologous cell sys-
tems in vitro [7].
To investigate the effect of the AD protective variant
P522R on PLCγ2 enzyme function, we firstly measured
production of 3[H] inositol phosphates in a radioactive
assay as described [26] upon transient transfection of
COS7 cells with pTriEx4-PLCG2 (common, “wild type”
variant; PLCG2 522P) construct, the AD associated
(P522R) construct, and with the D993G mutation (Ali5
[39]) construct. PLC activity after stimulation with EGF
showed a 1.24 ± 0.06 fold increase (mean value ± SD over
3 independent experiments, normalized to PLCγ2 WT
activity) upon transfection with the P522R construct
over the WT. For comparison, the inflammation-related
Ali5 p.D993G mutation exhibited a larger (2.27 ± 0.43
fold, mean value ± SD) increase in enzyme function upon
EGF stimulation (Fig. 4a).
Inositol phosphate IP1 accumulates over time and can
be measured by ELISA. As a second functional endpoint,
we therefore evaluated the enzyme activity of PLCγ2
p.P522R by measuring the cellular level of IP1 after acti-
vation of transfected epidermal growth factor receptor
(EGFR) into HEK293T cells. We confirmed expression
of the WT, the p.P522R variant, and EGFR (Fig. 4b,
A
B
Fig. 2 Plcg2 mRNA in microglia at amyloid plaques in a mouse model of AD. a RNAScope for Plcg2 in adult mouse neocortex and hippocampus of
TgAPPswe/ind transgenic mice. Note expression of Plcg2 in IBA-1-labeled microglia surrounding the plaques (DAPI). Arrows point to co-labeling of IBA-
1 and Plcg2. b RNAScope for Plcg2 in adult mouse hippocampus of a non-transgenic control mouse. Arrows point to co-labeling of IBA-1 and Plcg2
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Additional file 3). Stimulation of mock transfected cells
with EGF failed to increase IP1 level (Fig. 4c). The
expression of EGFR or EGFR + PLCγ2 significantly
increased the amount of IP1 confirming an activation of
the receptor and PLCγ2. p.P522R enzyme activity was
higher than PLCγ2, as measured by IP1 production
(Fig. 4c).
As a third endpoint of PLCγ2 function, we measured
real time changes in intracellular Ca2+. No Ca2+
changes were seen in mock HEK293T cells stimulated
with EGF (Fig. 4d), confirming our previous ELISA
IP-One results, and as previously observed [13].
Expression of EGFR induced significant intracellular
Ca2+ changes after addition of EGF, as measured by
increase of the 340/380 nm excitation ratio (Fig. 4d,
left panel). Quantification of the intracellular Ca2+
release showed a small but clear increase for p.P522R
variant as compared to WT PLCγ2 (Fig. 4d, middle panel).
Depletion of the intracellular Ca2+ stores activates a
Ca2+ flux across the plasma membrane, referred to as
store-operated Ca2+ entry or capacitative Ca2+ entry [41,
42]. This Ca2+ flux was observed by exposing the cell to
extracellular Ca2+ (Fig. 4d, right panel). Ca2+ level monitor-
ing show no significant differences in the extracellular Ca2+
B
A
Fig. 3 Plcg2 and Trem2 transcripts co-localize in the mouse brain. a Multiplex RNAScope for Plcg2 and Trem2 in the adult mouse cortex. Arrows
point to co-expression, arrowheads indicate single-labeled cells. b Multiplex RNAScope for Plcg2 and Trem2 in the adult mouse hippocampal CA1.
Arrows point to co-expression, arrowheads indicate single-labeled cells. Note co-localization in processes of putative microglia
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entry between cells expressing EGFR + PLCγ2 and EGFR +
p.P522R (Fig. 4d, right panel).
Discussion
Although single-cell transcriptomics of the human and
mouse cortex suggest enrichment of PLCG2 transcripts
in the microglia population, no spatial analysis has been
described for human and mouse tissue so far. In this
report, we characterized PLCG2 spatial expression in the
human and mouse brain.
One technical limitation of this study is that we
could not confirm mRNA and protein co-expression
in the same cells. However, in human cortical tissue,
we were able to show PLCγ2 immunoreactivity in
sparsely located cells with microglia-like morphology,
and PLCG2 transcripts were detected in similarly
sparsely distributed cells, reminiscent of microglia.
Together with the data of Plcg2 expression in mouse
tissue, our results strongly point to co-expression of
protein and mRNA, at least in microglia in the mam-
malian cortex.
In a modest, but significant number of cells in the
mouse cortex Plcg2 co-localized with a marker of endo-
thelial cells. According to a transcriptomic analysis of
cells in the vasculature, Plcg2 seems to be expressed in
certain subtypes of endothelial cells, although at lower







Fig. 4 PLCγ2 protective variant p.P552R shows a slightly hypermorphic activity by increasing intracellular calcium release. a PLC activity of the p.P522R variant
under basal and stimulated conditions. Measurement of % IP release in non-transfected COS7 cells (COS7), COS7 cells transfected with pEGFPC1-PLCG2
constructs (common variant, PLCG2 WT; AD associated, rare variant PLCG2 P522R; and PLCG2 D993G (Ali5) mutation. Western blotting was used to confirm
equal expression (anti-GFP, inset). SD is represented by error bars. The data are representative for 3 independent experiments. b HEK293T were transfected with
mock, EGFR, EGFR and PLCG2 WT, or EGFR and PLCG2 P522R plasmids. c Quantification of IP1 by ELISA IP-One. Transfected HEK293T cells were stimulated with
EGF 150 ng/ml and analyzed for IP1 quantification. ELISA reading were averaged of ± standard error (n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, #p
<0.05, ####p<0.0001, two-way ANOVA, Bonferroni multiple comparisons, *compared to control, #compared to EGFR). d Transfected HEK293T cells loaded
with Fura-2AM were stimulated with human EGF 150 ng/ml. Intracellular calcium level was recorded by calculating the 340/380 nm excitation ratio at each 5 s.
The net intracellular Ca2+ releases value was obtained by subtracting the average of 340/380 excitation ratio values between 0 and 50 s from the maximum
340/380 excitation ratio value between 60 and 200 s, after the EGF stimulation. The net extracellular Ca2+ entry value was obtained by subtracting the average
340/380 excitation ratio values between 285 and 380 s from the average of 340/380 excitation ratio values between 215 and 235 s after adding the extracellular
calcium. Data in d are shown as averages of ± standard error (*p<0.05, **p<0.01, ***p< 0.001, #p<0.05, ##p<0.01, ###p<0.001, & p< 0.05, one-way ANOVA,
Tukey’s multiple comparison test, *compared to mock, #compared to EGFR, & compared to PLCγ2. The “n” is corresponding to an average of 45 reading from
3 independent transfection). e Linear representation of the domains of PLCG2 with locations of the point mutations (Y495C, Ali14; P522R, AD protective variant;
S707Y, APLAID; D993G, Ali5)
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Another interesting finding is the detection of Plcg2 in
the granule cell layer of the dentate gyrus. The role of
Plcg2 in these neurons is unknown. By analogy with Plcg1
function in neurons, Plcg2 in granule cells may be relevant
for synaptic transmission and plasticity via induction of
hippocampal long-term potentiation LTP [10, 44]. Given
the involvement of the dentate gyrus in pattern separ-
ation—distinction of closely related memories—Plcg2 ex-
pression might be important for mnemonic functions.
Interestingly, to date, no deficits in learning and memory
have been described in Plcg2 −/− mice, or in humans
bearing the PLCG2 hypermorphic variants.
We showed that microglia are the main cell brain popula-
tion expressing Plcg2. The function of PLCγ2 in the immune
system has been studied in relation to autoinflammatory and
immune deficiency syndromes associated with PLCG2 muta-
tions in humans and mice [12, 13, 39]. In the brain, microglia
activation of Plcg2 might regulate intracellular calcium re-
lease, as shown for B cells [12, 45], and contribute to the
modulation of specific immune responses such as phagocyt-
osis, migration, proliferation, and survival. One receptor act-
ing upstream of Plcg2 and evoking such responses in innate
immune cells might be Trem2 [17, 46]. Indeed, human in-
duced pluripotent stem cell microglia-like cells harboring
mutations in TREM2 show distinct defects in phagocytosis
[47]. We found apparent co-localization of Plcg2 and Trem2
transcripts in microglia processes, which suggests a possible
requirement of local translation for quick responses to envir-
onmental changes, and a mechanism to detect neural tissue
damage. Mutations in TREM2 have been associated with in-
creased risk of AD [5, 18]. Moreover, increased levels of
Trem2 have been detected in disease-associated microglia
compared to microglia in a homeostatic state (37). We found
Plcg2 expression in microglia surrounding amyloid plaques
in a mouse model of AD as well as in “homeostatic” micro-
glia. This pathway, and in particular PLCγ2 activity, could be
critical for microglia function in neurodegenerative condi-
tions. Other potential signaling links of PLCγ2 variants with
upstream (ITGAM or FC receptors [14]) or downstream
(e.g., the NRLP3 inflammasome [48]) components in micro-
glia will be also addressed by our further studies.
Our functional analyses of the p.P522R variant reveal a
small hypermorphic effect on enzyme activity. The
molecular mechanism by which this occurs is currently
unknown. Other mutations in PLCG2 that lead to im-
mune dysfunction are known to be activating [7]. These
mutations have been proposed to affect enzyme function
by disruption of the autoinhibitory interface, destabilization
of the regulatory domain that blocks enzyme inactivation,
or alteration of interaction with the membrane. The pro-
tective variant P522R is certainly located within a region of
the enzyme that has a regulatory function (Fig. 4d, [7]),
which is consistent with this polymorphism modulat-
ing enzyme activation.
Conclusion
In summary, we show that PLCG2 is expressed in hu-
man and mouse brain microglia and that its expression
is maintained in microglia in close proximity to plaques
in the cerebral tissue of an APP mouse model. The
rare-coding AD protective variant shows a small hyper-
morphic activity upon stimulation in various orthogonal
cell-based assays. Further experiments will need to ad-
dress the functional consequences of the protective vari-
ant on immune cell phenotype. However, these findings
allow us to speculate that weak lifelong activation of
PLCγ2 might confer protection against developing AD,
and provide evidence that a limited activation of this en-
zyme may have a beneficial therapeutic effect. In com-
parison to previous studies which are aligned to the
concept that suppressing microglial function may be
beneficial in the setting of AD [49], the data described
here, together with studies on TREM2 and other
AD-associated variants, suggest that a different direc-
tionality may be therapeutically useful [6, 46, 50].
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